Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,531 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,887 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT05725421 | Transplantation of Reconstructed Renal Allografts Following Ex-Vivo Partial Nephrectomy | not yet recruiting | N/A | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06941480 | A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate | not yet recruiting | Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | not yet recruiting | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07748611 | SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial | not yet recruiting | Phase 2 | 125 | Northwestern UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749924 | Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC | not yet recruiting | N/A | 670 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750353 | A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas(XANTHOS) | not yet recruiting | Phase 2 | 35 | National Cancer Center, JapanOTHER_GOV | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07750704 | Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC | not yet recruiting | Phase 2 | 153 | Guangdong Association of Clinical TrialsOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06607874 | Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida | not yet recruiting | — | 100 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07178730 | NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer(ADAPT-TN-IV) | not yet recruiting | Phase 3 | 765 | Women's Cancer Study Group GmbHOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07209215 | ctDNA-Informed Management of Early-Stage Rectal Cancer(ULTIMATE) | not yet recruiting | Phase 2 | 200 | University of California, DavisOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07281547 | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain | not yet recruiting | Phase 4 | 20 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07468656 | SCLC Tarlatamab Blood Collection | not yet recruiting | — | 25 | Duke UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07552181 | Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer | not yet recruiting | Phase 2 | 50 | Yuan YuanOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07653594 | TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) | not yet recruiting | N/A | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07677475 | MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 2 | 65 | Dongguan People's HospitalOTHER_GOV | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07747506 | Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) | not yet recruiting | Phase 2 | 2 | Verastem, Inc.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07748260 | De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast(neoDIRHP) | not yet recruiting | Phase 3 | 592 | Guangdong Provincial People's HospitalOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07748481 | Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for Subcapsular Hepatocellular Carcinoma | not yet recruiting | — | 180 | The First Hospital of Jilin UniversityOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT07582003 | S-Adenosylmethionine (SAMe) for Chemoprevention of Colorectal Adenomas | not yet recruiting | Phase 1 | 18 | Jun Gong, MDOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.(SIGNAL-IO 301) | not yet recruiting | N/A | 920 | Natera, Inc.INDUSTRY | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07743632 | Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC(NeoASPECT) | not yet recruiting | Phase 2 | 110 | University of Kansas Medical CenterOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07744958 | RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer) | not yet recruiting | — | 100 | Heinrich-Heine University, DuesseldorfOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07745803 | Discovery and Validation of Biomarkers for Periodontitis, Dental Caries and Oral Squamous Cell Carcinoma | not yet recruiting | — | 4,000 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07151586 | Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer(ALTER) | not yet recruiting | Phase 2 | 260 | UNICANCEROTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07597252 | ctDNA Monitoring After Pancreatic Cancer Surgery (K-4CARE Lite Study)(K4CARE-PDAC) | not yet recruiting | — | 30 | Chang Gung Memorial HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07740993 | A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | not yet recruiting | Phase 2 | 25 | West China HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741344 | Study of Robotic Assisted/Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC | not yet recruiting | Phase 2 | 292 | Chinese University of Hong KongOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Early Phase 1 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07741643 | Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma | not yet recruiting | Phase 1 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07742956 | Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants. | not yet recruiting | Phase 2 | 156 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07135882 | Primary Radiotherapy In MEtastatic Lung Cancer(PRIME-Lung) | not yet recruiting | Phase 3 | 420 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738159 | Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma | not yet recruiting | Phase 2 | 92 | West China HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | not yet recruiting | Phase 1 | 120 | Iksuda Therapeutics Ltd.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739966 | A Study of DS-3939a in Participants With Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 400 | Daiichi SankyoINDUSTRY | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07733817 | Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.(PROBIOCOL) | not yet recruiting | N/A | 130 | Centre Francois BaclesseOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07470489 | Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer | not yet recruiting | Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732504 | AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation(HCC-AI-RECLAIM) | not yet recruiting | N/A | 2,000 | Tongji HospitalOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07732686 | Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry | not yet recruiting | — | 2,000 | University of OklahomaOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07734857 | Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma | not yet recruiting | — | 100 | Shanghai Zhongshan HospitalOTHER | 0 | Jul 29, 2026 | clinicaltrials |
| NCT07713732 | TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | not yet recruiting | Phase 1 | 120 | Treeline Biosciences, Inc.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07729917 | Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study | not yet recruiting | Phase 2 | 240 | Zhejiang UniversityOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07724951 | The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study | not yet recruiting | — | 400 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07726966 | Betacyanin for Early Diagnosis and Recovery of Anastomotic Leakage After Rectal Cancer Surgery: A Single-Center, Prospective, Controlled Trial | not yet recruiting | N/A | 120 | Southwest Hospital, ChinaOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07728955 | A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy(SCLC) | not yet recruiting | Phase 3 | 64 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT07729046 | Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer | not yet recruiting | Phase 2 | 150 | University of California, San DiegoOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07729592 | Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 0 | Jul 27, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials